University of Chicago

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of Chicago sits in the top decile of US sponsors by registered trial count (#41 of 15,742 sponsors by registered trial count).

796 total trials 158 currently recruiting 451 completed early-phase tilt top decile by trial count

University of Chicago: 796 sponsored US clinical trials, 158 recruiting.

University of Chicago sponsors 796 registered US clinical trials on ClinicalTrials.gov, 158 of them currently recruiting, and 451 completed. 67 of these trials are in Phase 3-4 (later-stage) and 293 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 11 trials.

Top-decile sponsor footprint

University of Chicago ranks in the top decile of sponsors by registered trial count (#41 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 40/100

451 of 562 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (80.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

796 total, page 7 of 16

COMPLETED NA

Inpatient Sleep Loss: Educating and Empowering Patients

NCT04151251
COMPLETED NA

CommunityRx-Hunger

NCT04171999
COMPLETED NA

CommunityRx-Dementia

NCT04146545
TERMINATED Phase 2

Phase II Trial of Neoadjuvant Pembrolizumab for Patients With Early Stage Gastroesophageal Adenocarcinoma

NCT04089904
TERMINATED

Hidradenitis - an Analysis of Genetic Traits and Linkages in Families

NCT05710393
COMPLETED NA

Intravascular Ultrasound (IVUS) Imaging During Transvenous Lead Extraction

NCT04055740
COMPLETED

Intraoperative Transesophageal Echocardiography Assessment of Portal Vein Flow and Renal Resistive Index As a Predictor of Acute Kidney Injury After Cardiac Surgery: A Prospective Observational Study

NCT04112953
TERMINATED Phase 2

Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL)

NCT03990961
COMPLETED Phase 4

Bowel Function After Minimally Invasive Hysterectomy

NCT04263896
COMPLETED Phase 2

De-Escalation Therapy for Human Papillomavirus Negative Disease

NCT03944915
TERMINATED NA

Effectiveness of Chest Compressions Under Mild Hypoxia

NCT04072484
COMPLETED Early Phase 1

Effects of Drugs on Responses to Brain and Emotional Processes

NCT04053036
COMPLETED NA

Lifestyle Intervention Feasibility for Arrhythmia and Symptoms With Intermittent Fasting (LIFE AS IF)

NCT04090840
TERMINATED Phase 4

A Study of Glutathione in Children With Autism Spectrum Disorder

NCT05954052
COMPLETED NA

A Narrative Intervention to Decrease Abortion Stigma

NCT03865199
COMPLETED NA

The Effects of Therapy Dogs on Child Biology and Behavior

NCT03949569
COMPLETED NA

Thirty Million Words-Early Childhood Educator (TMW-ECE)

NCT04027673
COMPLETED

Instrumented Data Exchange for Ataxia Study

NCT04268147
COMPLETED Early Phase 1

Behavior Brain Responses

NCT03964350
TERMINATED NA

A Pilot Study of High Intensity Walking in Older Adults in the Pre-operative Period

NCT04241419
COMPLETED NA

Intermittent Pneumatic Compression Device for Vein Dilation in Kidney Disease Patients to Enable AVF Creation (FACT)

NCT04063787
COMPLETED NA

Patient Outcomes Reporting for Timely Assessments of Life With Depression: PORTAL-Depression

NCT03832283
COMPLETED Phase 1

Mood Effects of Serotonin Agonists Extended

NCT03934710
COMPLETED NA

At Home Spirometry and Video Module Education for COPD Patients

NCT03834350
COMPLETED

Postoperative Tolvaptan Use in Left Ventricular Assist Device Implantation Patients

NCT05408104
COMPLETED NA

Effect of Noninvasive Electrical Brain Stimulation on Memory at Different Times of Day in Younger and Older Adults

NCT03723850
COMPLETED NA

Tracking Depression Symptoms With a Health Chatbot

NCT03990389
TERMINATED Phase 2

Azithromycin Treatment for the Airway Microbiome in Asthma

NCT03736629
TERMINATED Phase 1

Efficacy of Omega-3 Fatty Acid Therapy in Preventing Gastrointestinal Bleeding in Patients With CF-LVAD

NCT03784963
COMPLETED NA

Virtual Teach-to-Goal Education vs. Brief Education for Children

NCT04373499
COMPLETED Phase 2

Brexpiprazole in Borderline Personality Disorder

NCT03418675
COMPLETED Early Phase 1

Individual Differences in Drug Response

NCT03809546
COMPLETED

Propagation ANalysis for Arrhythmogenic Conduction Elimination to Prevent Atrial Flutter and Fibrillation (PANACEA-AF)

NCT03737838
COMPLETED NA

Managing Diabetes to Gain Opportunities for a More Active Life

NCT03692208
COMPLETED NA

Medical Care, Education, Social Support, And Goal-setting to Empower Self-management for Diabetes

NCT03487692
COMPLETED NA

Navigating Insurance Coverage Expansion (NICE)

NCT04263441
COMPLETED NA

Informing American Muslims About Living Donation

NCT04443114
COMPLETED NA

Magnetic Resonance Imaging for Detection of Peritoneal Mesothelioma

NCT03867578
COMPLETED Phase 1

Study of Acetazolamide With Temozolomide in Adults With Newly Diagnosed or Recurrent Malignant Glioma

NCT03011671
TERMINATED Phase 2

Pembrolizumab and EDP1503 in Advanced Melanoma

NCT03595683
COMPLETED Phase 2

Dronabinol in Trichotillomania and Other Body Focused Repetitive Behaviors

NCT03530800
COMPLETED NA

Developing an Imaging-Based Tool to Identify Areas for Prostate Cancer Biopsy

NCT03585660
COMPLETED

Florbetaben PET Imaging in PPA

NCT04720001
COMPLETED

CASH (Cavernous Angiomas With Symptomatic Hemorrhage) Trial Readiness

NCT03652181
TERMINATED Phase 1

Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer

NCT03572478
COMPLETED Phase 1

Atorvastatin Treatment of Cavernous Angiomas With Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial

NCT02603328
COMPLETED Phase 4

Trial Comparing Intrathecal Morphine With Placebo In Patients Undergoing Robotic Cardiac Surgery

NCT03241485
TERMINATED Phase 2

BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer

NCT02706691
COMPLETED

Patient Centered Postpartum Contraception App

NCT03402217
COMPLETED NA

CKD Report Card Pilot Trial

NCT04119570
← Previous Page 7 of 16 Next →

Phase Distribution

PhaseTrial count
Phase 1 137
Phase 2 156
Phase 3 14
Phase 4 53

Therapeutic Areas

Prostate Cancer 11
Head and Neck Cancer 8
Multiple Myeloma 6
Breast Cancer 6
COVID-19 5
Type 2 Diabetes 4
Kidney Stone 4
Surgery 4
Diabetes Mellitus, Type 1 4
Colorectal Cancer 4

What is open in the University of Chicago pipeline

158 recruiting of 796 indexed (20% open); 451 completed (57%).

Phase mix: 67 late (III/IV) vs 293 early (I/II) (early-phase heavy).

Top condition: Prostate Cancer (11 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of Chicago: open-pipeline peers nationwide

Peers matched on 796 registered trials and 20% open enrollment, not the therapeutic-area sidebar.

University of Chicago sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 02004006008001,000 14%16%18%20%22% Total trials Recruiting share University of ChicagoDana-Farber Cancer InstituteUniversity of California, San DiegoUniversity of UtahUniversity of Texas Southwestern Medical CenterAcera SurgicalAlign TechnologyAltruBioAlvernia University
University of Chicago sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of Chicago sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 796 trials (± recruiting share)

Sponsors near 20% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this University of Chicago page

796 registered trials is a research-attention snapshot, not an endorsement of University of Chicago or any single study.

  • 158 of University of Chicago's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Prostate Cancer is the condition University of Chicago studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of Chicago pipeline card: 796 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.